Literature DB >> 3287088

Adverse reactions and interactions of cyclosporin.

J P Scott1, T W Higenbottam.   

Abstract

Cyclosporin is a potent, widely used specific immunosuppressive agent which affects T-helper cells, and has little myelotoxicity. Its pharmacokinetics are complex and many of its actions remain poorly understood. Numerous side effects have been reported, affecting most organs. Most troublesome have been renal injury, systemic hypertension and vascular changes. Oral use is more effective than intramuscular and safer than the intravenous route. Interactions with other drugs include those which affect hepatic metabolism and those which reduce clearance. Aminoglycosides, macrolide antibiotics, imidazole derivatives, calcium channel blockers, sulphonamides and steroids are included in such interactions. Other metabolic effects of cyclosporin are more subtle and include hyperchloraemic alkalosis, changes in serum potassium and magnesium and effects on testosterone and prolactin levels. Acute poisoning with cyclosporin has been reported, again without myelosuppression. Cyclosporin is an important agent with multisystem toxicity, which requires precise monitoring of drug concentrations, liver and renal function, haemoglobin levels and plasma electrolytes. Cyclosporin pharmacodynamics and interactions with other drugs need to be carefully considered if lower rates of toxicity are to be achieved.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3287088     DOI: 10.1007/bf03259936

Source DB:  PubMed          Journal:  Med Toxicol Adverse Drug Exp        ISSN: 0113-5244


  206 in total

1.  The mechanism of hyperuricaemia in cyclosporine-treated renal transplant recipients.

Authors:  S L Cohen; G Boner; J B Rosenfeld; D Shmueli; O Sperling; A Yusim; A Todd-Pokropek; Z Shapira
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

2.  Endomyocardial biopsy: an overview.

Authors:  J J Fenoglio; C C Marboe
Journal:  Hum Pathol       Date:  1987-06       Impact factor: 3.466

3.  Interaction of cyclosporin A with antineoplastic agents.

Authors:  O Kloke; R Osieka
Journal:  Klin Wochenschr       Date:  1985-10-15

4.  Interstitial fibrosis in renal allografts in patients treated with cyclosporin.

Authors:  A Farnsworth; B M Hall; G G Duggin; J S Horvath; D J Tiller
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

5.  Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia.

Authors:  B Gloor; A Gratwohl; H Hahn; S Kretzschmar; Y Robert; B Speck; B Daicker
Journal:  Br J Ophthalmol       Date:  1985-05       Impact factor: 4.638

6.  Increased serum beta 2 microglobulin during rejection, cyclosporine-induced nephrotoxicity, and cytomegalovirus infection in renal transplant recipients.

Authors:  L Bäckman; O Ringdén; I Björkhem; B Lindbäck
Journal:  Transplantation       Date:  1986-10       Impact factor: 4.939

7.  Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study.

Authors:  A W van Rijthoven; B A Dijkmans; H S Goei The; J Hermans; Z L Montnor-Beckers; P C Jacobs; A Cats
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

8.  Renal function after acyclovir intravenous injection.

Authors:  D Brigden; A E Rosling; N C Woods
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

9.  Acutely impaired renal function during intravenous administration of cyclosporine A: a cremophore side-effect.

Authors:  G Thiel; M Hermle; F P Brunner
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

10.  Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis.

Authors:  T P Loughran; H J Deeg; S Dahlberg; M S Kennedy; R Storb; E D Thomas
Journal:  Br J Haematol       Date:  1985-03       Impact factor: 6.998

View more
  13 in total

1.  Once-a-day oral dosing regimen of cyclosporin A: combined therapy of cyclosporin A premicroemulsion concentrates and enteric coated solid-state premicroemulsion concentrates.

Authors:  C K Kim; H J Shin; S G Yang; J H Kim; Y K Oh
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  Intensive care management of children following heart and heart-lung transplantation.

Authors:  B Whitehead; I James; P Helms; J P Scott; R Smyth; T W Higenbottam; J McGoldrick; T A English; J Wallwork; M Elliott
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 3.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

4.  Early experience of heart-lung transplantation.

Authors:  R L Smyth; T W Higenbottam; J P Scott; J P McGoldrick; B Whitehead; P Helms; M de Leval; J Wallwork
Journal:  Arch Dis Child       Date:  1989-09       Impact factor: 3.791

5.  Interaction between cyclosporin and fluoxetine.

Authors:  R C Horton; R S Bonser
Journal:  BMJ       Date:  1995-08-12

Review 6.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 7.  Drug-induced nephrotoxicity. Aetiology, clinical features and management.

Authors:  A J Hoitsma; J F Wetzels; R A Koene
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

8.  Impairment of coronary flow reserve in orthotopic cardiac transplant recipients with minor coronary occlusive disease.

Authors:  P A Mullins; A Chauhan; L Sharples; N R Cary; S R Large; J Wallwork; P M Schofield
Journal:  Br Heart J       Date:  1992-09

9.  Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine.

Authors:  S T Brown; F F Edwards; E M Bernard; W Tong; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

Review 10.  Practical aspects in the use of cyclosporin in paediatric nephrology.

Authors:  P F Hoyer; J Brodehl; J H Ehrich; G Offner
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.